Scholarlink

<p>Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is indicated for people with HIV who are virologically suppressed, including those with M184V/I. Data on B/F/TAF effectiveness during viremia with M184V/I are limited. This observational study retrospectively collected clinical/demographic data from adults with viremia and M184V/I receiving B/F/TAF or alternate antiretroviral therapy (ART). Virologic suppression at 3 and ≥ 6 months was evaluated. For participants with data, 5/5 (100%) and 7/8 (88%) on B/F/TAF and 4/6 (67%) and 7/10 (70%) on alternate ART achieved virologic suppression at 3 and ≥ 6 months, respectively. Virologic suppression was achieved in most people with HIV who were viremic with M184V/I on B/F/TAF, as with alternate ART.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Charlotte-Paige Rolle,
  • Michelle L. D’Antoni,
  • Roberto Corales,
  • Andrea Marongiu,
  • Joshua Gruber,
  • Tanya Schreibman,
  • Dionne Bell,
  • Chiu-Bin Hsiao,
  • Indira Brar

摘要

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is indicated for people with HIV who are virologically suppressed, including those with M184V/I. Data on B/F/TAF effectiveness during viremia with M184V/I are limited. This observational study retrospectively collected clinical/demographic data from adults with viremia and M184V/I receiving B/F/TAF or alternate antiretroviral therapy (ART). Virologic suppression at 3 and ≥ 6 months was evaluated. For participants with data, 5/5 (100%) and 7/8 (88%) on B/F/TAF and 4/6 (67%) and 7/10 (70%) on alternate ART achieved virologic suppression at 3 and ≥ 6 months, respectively. Virologic suppression was achieved in most people with HIV who were viremic with M184V/I on B/F/TAF, as with alternate ART.